Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.70 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.70 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.70 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.70 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.70 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17510010 | 0.89 | HDAC3 (0.66) | TP53HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL18376685 | 0.89 | HDAC3 (0.76) | TP53HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL517051 | 0.89 | HDAC3 (0.87) | TP53HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6029300 | 0.87 | TP53 (0.70) | TP53HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL19525768 | 0.87 | TP53 (0.70) | TP53HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8817395 | 0.87 | HDAC3 (0.76) | TP53HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL24733190 | 0.86 | POLB (0.65) | TP53HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL22923581 | 0.86 | HDAC3 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17252161 | 0.86 | HDAC3 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9312728 | 0.86 | HDAC3 (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023164655-A1 | DUPILUMAB FOR TREATMENT OF COVID-19 | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2023-08-31 | — | — | WO | disclosed |
| US-10752617-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-08-25 | — | — | US | disclosed |
| US-20190202819-A1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-07-04 | — | — | US | disclosed |
| CN-105307655-B | Pyridazinone compound and its be used to prepare treatment tumour shape fibrosis drug application | 弗拉特利发现实验室有限责任公司 | 2019-05-03 | — | — | CN | disclosed |
| US-10246440-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-04-02 | — | — | US | disclosed |
| EP-3233836-B1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RES & DEV (FR) | 2019-01-30 | — | — | EP | disclosed |
| US-20170342062-A1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-11-30 | — | — | US | disclosed |
| EP-0440503-A1 | 4-Isoxazolecarboxamide derivatives | SYNTEX (U.S.A.) INC. (US) | 1991-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246440-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T)) | RORA, RORB, RORC | TP53 1383/4885HDAC3 357/4885HDAC4 1287/4885 |
| US-20170342062-A1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | RORA, RORB, RORC | TP53 1388/4885HDAC3 349/4885HDAC4 1318/4885 |
| US-20190202819-A1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | RORA, RORB, RORC | TP53 1388/4885HDAC3 349/4885HDAC4 1318/4885 |
| US-10752617-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) | RORA, RORB, RORC | TP53 1388/4885HDAC3 349/4885HDAC4 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.